Briacell Therapeutics Corp faces a challenging week as its stock sees a decline amid no major news developments.
Briacell Therapeutics Corp (BCT.TO) has experienced a notable downturn in its stock price this week, closing at C$4.82, down 5.49% for the day and 4.17% for the week. This decline comes despite no significant announcements or developments from the company, leaving investors to navigate the current market sentiment.
Advertisement
Earn cash back with a smarter spending account
Open a KOHO account and start earning on everyday purchases — no annual fee on the base plan.
Briacell Therapeutics Corp
BCT.TO
BCT.TO
Briacell Therapeutics Corp
WealthAwesomeMarket cap
$41.93M
52W high
$20.40
52W low
$3.68
1W change
-4.17%
Beta
1.54
Analyst Price Targets
Based on analyst covering BCT
Wall Street analysts forecast BCT stock price to rise 314.9% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$20.00
+314.9% Upside
Current Price
C$4.82
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on BCT's historical volatility
30-Day Vol
61.9%
Annualized
90-Day Vol
83.4%
Annualized
Trend (90d)
-50.0%
Annualized drift
90d Mean
C$4.03
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$4.54 | C$3.67 – C$5.62 |
| 60 trading days | C$4.28 | C$3.16 – C$5.79 |
| 90 trading days | C$4.03 | C$2.79 – C$5.84 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Investor takeaway: Current market conditions and the lack of recent news may lead investors to approach Briacell Therapeutics with caution, especially considering its significant year-to-date decline of nearly 51%.
C$4.82 closing price, down 5.49% today.
Briacell's stock has seen a staggering decline of 50.92% year-to-date, highlighting ongoing challenges in the market.
Bull case
Briacell's Bria-OTS+™ platform has shown promising preclinical data in cancer treatment. This positive information could attract future investor interest and potentially boost the stock's value.
Bear case
The company's stock has decreased significantly over the past year. Its current fundamentals, including a profit margin of 0.0% and negative return on equity (ROE), raise concerns about its financial health and sustainability.
Recent Price Action
Advertisement
Briacell Therapeutics Corp's stock closed at C$4.82, reflecting a 5.49% drop for the day and a 4.17% decrease over the week. The stock's performance has been challenging, particularly when juxtaposed against its year-to-date decline of 50.92%. Investors are likely to take note of this downward trend as the company continues to navigate a competitive healthcare landscape.
Technical Picture
Currently, Briacell's stock is trading above its 50-day moving average of C$4.69 by 2.7%, indicating a short-term bullish sentiment. However, it remains significantly below its 200-day moving average of C$7.92, down 39.2%. The stock has a 52-week range of C$3.68 to C$20.40, suggesting that it is currently trading at approximately 7% of its range. The stock has a beta of 1.54, indicating higher volatility compared to the market. Notably, the latest trading volume was 2,442 shares, which is only 40% of the 20-day average volume of 6,050 shares, suggesting lower investor interest.
Recent Company News
Despite the stock's decline, there have been no major announcements or news releases from Briacell Therapeutics this week. However, previous headlines indicate ongoing developments in their research, including the positive preclinical data for the Bria-OTS+™ platform. This data, showcased at the AACR Annual Meeting in April 2026, demonstrated promising anti-cancer activity, which could potentially influence future investor sentiment and stock performance.
Advertisement
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
